Drug intelligence / Profile preview

autologous CD8+ antigen-specific T cells

Development stage: Phase 2
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Cell Therapies
Administration: Intrathecal

Overview

Investigational autologous CD8+ antigen-specific T-cell therapy developed by M.D. Anderson Cancer Center for the treatment of leptomeningeal melanoma. The therapy involves the ex vivo expansion of a patient's own CD8+ T cells, which are then administered intrathecally to target melanoma cells that have metastasized to the leptomeninges. This localized delivery method is intended to overcome the limitations of the blood-brain barrier in treating central nervous system involvement of melanoma.

Other names: Intrathecal autologous CD8+ T cellsCD8+ antigen-specific T cells

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on autologous CD8+ antigen-specific T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous CD8+ antigen-specific T cells.

Explore the full profile